Effectiveness of intramuscular neostigmine to accelerate bladder emptying after spinal anesthesia

Figures & data

Table 1 Subject characteristics

Characteristics	Groups		P-value
	N (n=18)	C (n=18)
Sex
Male	8 (44.4%)	8 (44.4%)	1.000a
Female	10 (55.6%)	10 (55.6%)
Age (years)	34.1±12.9	37.5±13.7	0.443b
BMI (kg/m^2)	22.3±1.5	22.5±2.5	0.763b
ASA physical status
ASA I	9 (50%)	9 (50%)	1.000a
ASA II	9 (50%)	9 (50%)

Notes: Values are expressed as mean±SD for numerical data and frequency (%) for categorical data.

a χ² test.

b Independent t-test.

Abbreviations: ASA, American Society of Anesthesiologist; BMI, body mass index; C, control group; N, neostigmine group; n, number of subjects.

Table 2 Intraoperative

Intraoperative	Groups		P-value
	N (n=18)	C (n=18)
Local anesthetic dose (mg)	12.5 (10–15)	15 (7.5–15)	0.237a
Sensory block level (T)	8 (6–9)	7 (6–10)	0.399a
Surgical duration (minutes)	81.5±26.6	77.8±34.1	0.717b
Volume of IV fluid (mL)	1,000 (500–1,000)	1,000 (500–1,500)	0.063a

Notes: Values are expressed as mean±SD or median (minimum–maximum) for numerical data and frequency (%) for categorical data.

a Independent t-test.

b Mann–Whitney U test.

Abbreviations: C, control group; IV, intravenous; N, neostigmine group; n, number of subjects; T, thoracic dermatome.

Table 3 Postoperative

Postoperative	Groups		P-value
	N (n=18)	C (n=18)
Urinary bladder volume before treatment (mL)	445.6±75.9	486.1±72.4	0.110a
Time to first voiding after treatment (minutes)	41.9±12.3	89.4±26.1	<0.001b
	40 (20–70)	75 (55–135)
Time to first voiding after spinal anesthesia (minutes)	280.8±66.6	364.2±77.3	0.001a
Volume of urine excreted (mL)	243.1±62.8	289.7±86.2	0.063b
	230 (150–400)	322 (150–400)
Postvoid residual volume (mL)	112.5±17.8	190±23.3	0.001a
Patients who needed urinary catheterization	1 (5.6%)	3 (16.7%)	0.603c

Notes: Values are expressed as mean±SD and/or median (minimum–maximum).

a Independent t-test.

b Mann–Whitney U test.

c Fischer’s exact test, treatment=IM injection of neostigmine or NaCl 0.9%.

Abbreviations: C, control group; IM, intramuscular; N, neostigmine group; n, number of subjects.